Jump Financial LLC Cuts Position in Boston Scientific Co. (NYSE:BSX)

Jump Financial LLC trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX) by 42.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 164,977 shares of the medical equipment provider’s stock after selling 121,091 shares during the period. Jump Financial LLC’s holdings in Boston Scientific were worth $14,736,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. M&T Bank Corp lifted its position in Boston Scientific by 0.3% during the third quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock worth $8,894,000 after buying an additional 370 shares during the period. Passumpsic Savings Bank purchased a new stake in Boston Scientific during the third quarter valued at about $3,015,000. World Investment Advisors LLC raised its holdings in Boston Scientific by 50.9% in the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock valued at $979,000 after buying an additional 3,939 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Boston Scientific during the 3rd quarter worth $1,175,000. Finally, Tidal Investments LLC raised its holdings in shares of Boston Scientific by 8.8% during the 3rd quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider’s stock valued at $7,249,000 after buying an additional 6,990 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 6,528 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. Piper Sandler upped their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. UBS Group boosted their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. JPMorgan Chase & Co. raised their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Finally, Barclays boosted their price target on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $109.04.

Boston Scientific Stock Up 0.6 %

Shares of NYSE:BSX opened at $94.20 on Tuesday. The company has a market capitalization of $139.33 billion, a PE ratio of 75.36, a PEG ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a 50 day moving average price of $100.32 and a two-hundred day moving average price of $94.18. Boston Scientific Co. has a 52 week low of $66.80 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.